Clinical features and efficacy of reperfusion therapy in minor ischemic stroke patients with atrial fibrillation
AbstractThe efficacy of reperfusion therapy (RT) using intravenous infusion of recombinant tissue plasminogen activator and/or endovascular therapy for minor ischemic stroke (MIS) has not yet been established. The present study aimed to elucidate the clinical features of MIS patients with atrial fibrillation (AF) and examine whether they could be potential candidates for RT. Data of MIS patients, defined as those with a score ≤ 5 on the National Institute of Health Stroke Scale, were extracted from patients admitted to our hospital between 2006 and 2018, and clinical characteristics were compared between the AF and non-AF groups. Thereafter, the impact of RT on outcomes in the AF- group was evaluated using the mod ified Rankin scale (mRS) score 3 months after onset and compared to that of standard medical therapy (SMT) using propensity score matching (PSM). Of 10,483 stroke patients, 3003 were shortlisted, and 457 AF patients and 2546 non-AF patients were finally selected. Patients in the AF group had more R T (13.3% vs. 5.7%, p
Authors: Hou Y, Liu Y, Li M, Ning B, Wen Z, Fu W Abstract Objectives: To systematically assess the efficacy of acupuncture combined with rehabilitation on unilateral neglect after stroke. Methods: The Cochrane Library, PubMed, Excerpt Medical Database (EMBASE), China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), Chinese Biomedical Literature Database (CBM), and Wan Fang databases were searched online for randomised controlled trials (RCTs) of acupuncture and its effects on unilateral neglect after stroke from their inception to September 2019. RCTs on acupuncture...
Publication date: Available online 8 April 2020Source: Materials Today: ProceedingsAuthor(s): S. Jagadeesh, K. Narayanamoorthy, K. Ramesh, K. Gnanasekaran, S. Prathap Singh
Publication date: Available online 7 April 2020Source: NeuroImageAuthor(s): Jingfei Li, Godwin Ogbole, Benjamin Aribisala, Murtala Affini, Joseph Yaria, Issa Kehinde, Alade Rahman, Fakunle Adekunle, Rasaq Banjo, Moyinoluwalogo Faniyan, Mayowa Owolabi, Steffen Sammet
BOSTON (CBS) — TPA is a drug that is used to help stroke and heart attack victims. It works by breaking up or busting blood clots. Doctors at Beth Israel Deaconess Medical Center are now using it in a clinical trial on gravely ill coronavirus patients. “There’s a lot of very small blood clots accumulating in the lungs of these patients,” said Dr. Christopher Barrett. “And that seems to be at least contributory, if not the predominant reason, that their respiratory failure is so bad.” Dr. Barrett says TPA could help patients recover faster, free up ventilators and even prevent people from...
Conclusion: The results of this study indicate that our pneumonectomy outcomes are acceptable despite high morbidity and mortality rates. Appropriate patient selection for pneumonectomy is as important as complication management. High-comorbidity patients should undergo these procedures in experienced centers. PMID: 32254000 [PubMed - as supplied by publisher]
AbstractSince the outbreak of the COVID-19 epidemic which in our region, Veneto (Italy), dates back to February, we were confronted with several challenges, but with a constant aim of keeping our Stroke Unit COVID-free. For this reason, in addition to creating a dedicated hot-spot as a pre-triage just outside the Emergency Department, together with the Neuroradiology Unit we obtained a mobile CT unit that could be used by COVID-positive or COVID-suspected patients. Furthermore, thanks to the collaboration with colleagues from different specialties (Infectious Disease, Internal Medicine, Intensive Care, Emergency Medicine),...
Conclusion: The most important finding of one-month ticagrelor consumption were dyspnea, bleeding, and hypersensitivity reaction. No case of bradycardia and stent thrombosis was detected. In our study , iranian population has more susceptibility to dyspnea than PLATO result. The rate of drug discontinuation in this series of cases was 6.4 %. PMID: 32259131 [PubMed - as supplied by publisher]
Authors: Samaras A, Kartas A, Vasdeki D, Dividis G, Forozidou E, Fotos G, Kotsi E, Paschou E, Tsoukra P, Goulas I, Karvounis H, Giannakoulas G, Tzikas A PMID: 32259588 [PubMed - as supplied by publisher]
Conclusion: Risk factors, aetiology, and precipitating factors of HF in de novo and ADCHF differ. De novo HF also had lower 1-year mortality and 3-month mortality compared to ADCHF. PMID: 32252602 [PubMed - as supplied by publisher]